Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Ascentage Pharma Group International ( (HK:6855) ).
Ascentage Pharma Group International has announced the offering of American Depositary Shares (ADS) and the issuance of new ordinary shares under a general mandate. The company will offer 7,325,000 ADSs, each representing four newly issued ordinary shares, and has granted underwriters a 30-day option to purchase an additional 1,098,750 ADSs. This strategic move is expected to enhance its capital base and provide greater financial flexibility, potentially strengthening its market position and investor appeal in the biopharmaceutical industry.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company focused on developing therapies for cancer, hepatitis B, and age-related diseases. It operates in the pharmaceutical industry, primarily offering a pipeline of innovative drug candidates targeting key mechanisms in the treatment of tumors and other serious illnesses.
YTD Price Performance: -14.85%
Average Trading Volume: 1,793,400
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$12.08B
Learn more about 6855 stock on TipRanks’ Stock Analysis page.
